United Kingdom Approves Inne's Saliva Test: Paving the Way for Revolution in Birth Control
The healthtech startup, Inne, has made a significant breakthrough in the contraceptive industry with the launch of its innovative Minilab saliva test device. This non-invasive, home-use gadget is designed to track fertility hormones, specifically progesterone, offering a hormone-free alternative to the contraceptive pill.
The Minilab device is simple to use, requiring daily testing. It employs a lateral flow assay, similar to COVID-19 or pregnancy tests, combined with an electronic reader and app for analysis and updates on hormone levels and fertility status.
In a year-long clinical study involving 300 women and over 1,500 cycles, the Minilab was certified as a new modern contraception method. The study found that the device was 100% effective with perfect use (no unprotected intercourse during fertile windows) and 92% effective under typical use conditions, comparable to combined hormonal contraceptive pills and superior to condoms.
Eirini Rapti, co-CEO and founder of Inne, stated that the Minilab puts women's biological data at the centre, offering a hormone-free alternative to the contraceptive pill. The device is not just for contraception but is a platform for women's health data and insights.
Inne plans to take the Minilab to the next level by adding additional analysis and algorithms, such as cortisol for stress and perimenopause, to provide more data and information for women.
It's important to note that while the Minilab has received regulatory approval in Europe, the clinical study behind its approval was observational with a relatively small sample size and has not yet been peer-reviewed. Further large-scale, long-term studies are needed to confirm sustained efficacy and reliability.
Despite the need for further validation, the Minilab represents a significant innovation in contraceptive technology. As a saliva-based contraceptive device, it offers a hormone-tracking alternative that does not carry the side effects of hormonal methods such as mood changes, weight gain, or blood clot risks.
The Minilab brings a new level of scientific rigor and personalization to fertility awareness-based contraception, which historically had lower effectiveness due to user error. It uses a digital, image-recognition algorithm combined with biochemical testing to provide daily personalized fertility insights, a step forward from traditional fertility awareness methods that rely on temperature or calendar tracking.
In a world where approximately 160 million women globally have unmet contraception needs, according to a Lancet study, the Minilab offers a much-needed solution. Across Europe, nearly 40% of women rely on old-fashioned methods like withdrawal for contraception.
Inne aims to continue providing tools for women to understand their health at critical life stages, making the Minilab a burgeoning healthcare platform rather than just a contraception method.
The Minilab device, developed by healthtech startup Inne, is not solely a contraception method but also a platform for women's health data, expanding to include analysis of cortisol for stress and perimenopause, thereby delving into health-and-wellness and womens-health aspects.
In the realm of science, the Minilab brings a new level of personalization to fertility awareness-based contraception, with a potential to address the unmet contraception needs of approximately 160 million women globally.
